Introduction: This phase II clinical trial aimed to investigate the efficacy and safety of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF regimen) followed by concurrent chemoradiation in patients with locally advanced nasopharyngeal carcinoma.
Results: Overall, 74 courses of induction chemotherapy were administered. After induction chemotherapy, overall response rate was 84%. However, only one patient achieved a pathologic complete response. At the end of concurrent chemoradiation, 24 patients (96%) achieved clinical and pathologic complete response at both nasopharynx and regional nodes and one (4%) had persistent disease. Treatment-related toxicities were common but manageable. Grade 1-2 anemia was the most hematologic toxicity being detected in 51 cycles (68.9%) of induction chemotherapy. Four patients developed uncomplicated, culture-negative febrile neutropenia. There was no treatment-related death.
Conclusion: Induction chemotherapy with TPF regimen followed by concurrent chemoradiation is highly effective with manageable toxicity in patients with locally advanced nasopharyngeal carcinoma.
Introduction
Despite the low incidence rate of nasopharyngeal carcinoma (NPC), the age distribution for NPC is younger than that for other head and neck sites. Approximately 20% of the patients are younger than 30 years of age. 1 It is also the most frequent carcinoma of the head and neck malignancy in pediatric and young adolescent population. 2 Locally advanced NPC refers to a group of NPCs demonstrating advanced disease in nasopharynx or regional lymph nodes without evidence of distant metastasis. Approximately 50% of NPCs are locally advanced at presentation. 3 Compared to other head and neck cancers, surgery plays a limited role in treating NPC. Distinctive anatomical location and vicinity of NPC to skull base neurovascular structures prevent curative surgery. 4, 5 However, NPC is a highly radiosensitive tumor and radical external beam radiotherapy with or without chemotherapy remains the mainstay of treatment for this neoplasm. Concurrent chemoradiation is currently the standard of care for locoregionally advanced NPCs. 5 Locoregional and systemic failures are high in patients with locally advanced disease and contribute to poor survival. [4] [5] [6] Consequently, more effective chemotherapeutic regimens and other systemic therapy are needed to decrease the rate of locoregional and distant failure and improve survival.
Previous studies confirmed the efficacy and the feasibility of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF regimen) regimen in locally advanced head and neck cancers. 7, 8 In addition, the tolerability and efficacy of concurrent chemoradiation with weekly cisplatin have been proven in patients with locally advanced NPC. The present phase II clinical trial aimed to investigate the response rates of induction chemotherapy with TPF regimen followed by concurrent chemoradiation in treatment of locally advanced NPCs.
Patients and methods
This phase II clinical trial enrolled 28 patients with diagnosis of NPC who were referred to Namazi academic hospital for treatment between April 2011 and March 2012. Eligible patients were aged between 15 and 70 years and had to have newly diagnosed locally advanced NPC stage classification III-IV B (T3-T4 and/or N2-N3, M0) based on the criteria used in the 7th edition of the American Joint Committee on Cancer (AJCC) Staging system, 9 Karnofsky Performance Status (KPS) P70, and normal or adequate kidney, liver, cardiovascular, and bone marrow functions. In this study we considered a serum creatinine <1.4 mg/dl, and creatinine clearance >60 ml/min as adequate renal function. The study was approved by the Clinical Research Ethics Committee of Shiraz University of Medical Sciences in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. Written informed consent was obtained from all patients before trial entry. Exclusion criteria were prior therapy, any evidence of distant metastases before or during the trial, known contraindication for chemotherapy (such as allergy to taxan drugs), positive history of receiving radiotherapy for other head and neck neoplasms, documented heart, liver, renal or blood coagulation diseases, and patients' refusal to participate in the trial or to sign on the consent form.
Patient evaluation
Pre-treatment evaluation included a complete medical history, physical examination with special attention on the status of cervical lymph nodes regarding their size, location and fixation, assessment of KPS, direct nasopharyngoscopy to determine tumor extension and taking biopsy, chest radiograph, ultrasound imaging of the abdomen and contrast-enhanced Computed Tomography (CT) scan of the nasopharynx and neck. Disease staging was defined according to the 7th edition of AJCC staging system. 9 Other tests included complete blood count (CBC), liver function tests (LFT) and renal function test (RFT). Baseline audiogram was performed for all patients. Whole body bone scintigraphy was performed in symptomatic patients or those with elevated alkaline phosphatase level. In addition, cardiovascular evaluation was carried out in high risk patients (age greater than 60 years, heavy smoker and background diseases like hypertension or diabetes mellitus). All patients were carefully evaluated for dental carry and all needed dental repairs and treatment were completed well before starting radiation therapy.
Treatment
All patients were assigned to receive induction chemotherapy in an outpatient setting every 3 weeks for 3 cycles with TPF regimen (docetaxel 75 mg/m 2 for day 1, cisplatin 75 mg/m 2 for day 1, 5-FU 750 mg/m 2 /day with 8-h infusion on days 1-3). Antiemetic medication including a selective 5-hydroxytryptamine-3 (5HT3) antagonist and steroids were prescribed intravenously for all chemotherapy cycles. In addition, prophylactic colony stimulating factor (as 5 lg/kg filgrastim) was considered for all patients following each cycle of TPF regimen during days 5-9. Clinical condition, regional lymph node status, treatment toxicity and patients' complaints were evaluated and recorded before each cycle of chemotherapy.
Three weeks after completion of induction chemotherapy, all patients were assigned to receive concurrent chemoradiation with weekly cisplatin (30 mg/m 2 ) from the first day of radiation therapy (RT), up to 7 cycles. External beam RT using megavoltage telecobalt unit or linear accelerator (6 MV) was performed. The nasopharynx and regional cervical lymph nodes were treated with conventional fractionation and a total dose of 70 Gy was delivered in 35 fractions (5 fractions per week). The primary site and upper cervical lymph nodes were treated with two lateral parallel opposed fields; and the lower cervical lymph nodes were treated with a separate en face anterior field with a central block. The spinal cord was excluded from the radiation fields after 44 Gy. After 50 Gy, RT was continued to the primary site up to 70 Gy. Metastatic lymph nodes received a boost dose of 15-20 Gy.
Each cycle of induction chemotherapy or weekly cisplatin was administered only if the general condition of the patient and blood tests were acceptable (Hb P 9 g/dl, absolute neutrophil count [ANC] P 1500, platelet P 100000, SGPT, SGOT, ALP 6 1.5 fold of normal upper limit, normal bilirubin and creatinine). Tumor response was evaluated at the end of induction chemotherapy and again 4 weeks after completion of concurrent chemoradiation. Response evaluation included clinical examination and CT scan of the nasopharynx. In addition, in patients with complete clinical and radiologic response, direct nasopharyngoscopy and biopsy of the nasopharynx were done to evaluate the pathologic response. All CT scan images were reviewed by the same radiologist.
Tumor response evaluation was based on Response Evaluation Criteria In Solid Tumors (RECIST) as follows: complete response was defined as the complete disappearance of all assessable lesions; partial response as over 30% reduction in the sum of the longest diameters of all measurable disease compared with baseline; stable disease as less than 30% reduction or less than 20% increase in the sum of the longest diameters of all measurable disease; and progressive disease was defined as more than 20% increase in the longest diameters of original measurable disease or the appearance of a new lesion. 10 Treatment complications during induction chemotherapy and concurrent chemoradiation were recorded using version 4.0 (the last version) of Common Terminology Criteria for Adverse Events (CTCAE). Clinical response rates and safety were the primary and secondary endpoints, respectively.
Statistical methods
The chi-squared (v 2 ), Fisher's exact, and Mann-Whitney tests were used for comparing the clinical response rates and the clinicopathological characteristics of the trial arms. The statistical analysis was performed according to the sum of the longest diameters of all measurable lesions. A minimum sample size required 24 patients to ensure 80% power with 5% confidence interval. Data analyses were done with Wilcoxon and Friedman tests, and carried out using SPSS Software, version 17.
Results
Twenty eight patients with locally advanced NPC were enrolled in this study. After excluding three patients who developed skeletal metastases or refused to continue induction chemotherapy 25 patients participated in the study. Patient characteristics are listed in Table 1 .
Overall, 74 courses of induction chemotherapy with TPF regimen were administered for the patients. Only one of the patients could not receive the third cycle of induction chemotherapy because of severe drug reaction to docetaxel (grade 4 dyspnea) during the second course of chemotherapy.
Three weeks after the last cycle of induction chemotherapy, 12 patients (48%) achieved a clinical complete response and 10 (40%) achieved a clinical partial response. Therefore, after induction chemotherapy, overall response rate was 84%. However, direct nasopharyngoscopic and pathologic examination revealed that only one patient (4%) achieved a pathologic complete response and 20 (80%) achieved a partial response and residual disease in the nasopharynx. The overall (complete and partial) clinical and pathologic response rates to neoadjuvant chemotherapy were 88% and 84% respectively ( Table 2 ).
Subsequently the patients received a median total radiation dose of 70 Gy (range 64-70 Gy) concurrently with median 6 cycles (range 4-7 cycles) of weekly cisplatin. Four weeks after completing concurrent chemoradiation, 21 patients (82%) achieved a clinical complete response at both nasopharynx and regional nodes and 4 (18%) showed residual nasopharyngeal soft tissue in CT scan (Table 2 ). However, in direct naso-
The efficacy and safety of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in treating patients with locally advanced nasopharyngeal carcinoma 109 pharyngoscopy and pathologic examination only one patient had persistent disease and the three remaining patients showed no evidence of malignancy and there was chronic inflammation and necrosis. Therefore, by considering these results, after completion of the therapy 24 patients (96%) achieved a pathologic complete response. Overall, treatment-related toxicities were common but manageable (Table 3 ). During 74 cycles of chemotherapy grade 1-2 anemia was the most hematologic toxicity, being detected in 51 cycles (68.9%). Four patients developed uncomplicated, culture-negative febrile neutropenia. Grade 3 nausea and diarrhea occurred in 8.1% and 1.35% of the cycles, respectively.
Toxicity related to concurrent chemoradiation was tolerable (Table 4) , with grade 3 neutropenia and anemia occurred in 12% and 4% of patients, respectively. Grade 3 nausea, oral mucositis and xerostomia developed in 40%, 24%, and 20% of patients, respectively. Due to these non-hematologic toxicities, radiotherapy was interrupted in 8 patients (32%) and finally stopped before 70 Gy in 5 patients (20%). There was no treatment-related death.
Discussion
NPC has different epidemiologic and biologic features than those of other head and neck SCCs. 11, 12 It is more common in china and is rare in west countries. 12 Locally advanced NPCs tend to develop high rates of locoregional and distant failure and have poor prognosis. The 5-year survival rate with radiotherapy alone is 15-50%. 12, 13 Early studies found that sequential chemotherapy with cisplatin and 5-fluorouracil following radiotherapy alone or chemoradiation induced higher rates of complete response and better survival. However, this Table 3 The rate of chemotherapy-related toxicity during 74 cycles of induction chemotherapy. approach was not well tolerated and was associated with increased toxicity. 12, 13 Induction chemotherapy followed by concurrent chemoradiation is more likely to be successfully administered than adjuvant chemotherapy following concurrent chemoradiation. Therefore, recent trials focused on induction chemotherapy and showed promising results of induction cisplatin-based chemotherapy followed by concurrent chemoradiation in treatment of locally advanced NPCs. However, overall survival was not statistically significant. 14 The goal of induction chemotherapy in NPC is to eradicate micrometastasis, downstaging the primary tumor and metastatic regional lymph nodes and improve response rate to the chemoradiation. 12, 13 The other probable benefit of neoadjuvant chemotherapy is improvement in radiation delivery to target. 12 Rischin et al, in a phase II trial evaluated the effect of 3 cycles of neoadjuvant epirubicin, cisplatin, 5-fluorouracil (ECF) followed by chemoradiation in locally advanced NPC. Overall clinical response was 89% and complete clinical response was 40%. The 4-year progression-free and overall survival rates were 81% and 90% respectively. 12 Subsequent clinical trials found that the addition of docetaxel or paclitaxel to cisplatin and 5-fluorouracil induction chemotherapy improved the efficacy of induction chemotherapy with manageable toxicities in patients with NPCs. 15, 16 Guo et al in a phase I study tried to define the best tolerable dose for TPF regimen. They started induction chemotherapy with docetaxel 40 mg/m 2 day 1, cisplatin 40 mg/m 2 day 1, and 5-FU 400 mg/m 2 days 1-5. They gradually escalated the doses and found neutropenia , mucositis and diarrhea were the dose limiting factors. Finally, they recommended docetaxel 60 mg/m 2 day 1, cisplatin 60 mg/m 2 day 1, and 5-FU 600 mg/m 2 days 1-5. 17 In our study, the dose of drugs was docetaxel 75 mg/m 2 , cisplatin 75 mg/m 2 and 5-FU 750 mg/m 2 for 3 days.
There are multiple clinical trials evaluating induction cisplatin-based chemotherapy with taxanes followed by concurrent chemoradiation in locally advanced or metastatic nasopharyngeal carcinoma, 15, 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Table 5 ). These promising results showed that the addition of a taxane (docetaxel, paclitaxel) to cisplatin-based induction chemotherapy improved response rates and survival rates. In addition, this table shows that hematologic (particularly neutropenia) and gastrointestinal (particularly mucositis, diarrhea and emesis) toxicities are the most important adverse effects.
The response rates to therapy and major toxicity of the present study were consistent with other studies ( Table 5 ).
Conclusion
Induction chemotherapy with TPF is highly effective with acceptable and manageable toxicity in treating patients with locally advanced nasopharyngeal carcinoma. Further followups are needed to translate these results into an advantage in overall survival. The efficacy and safety of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in treating patients with locally advanced nasopharyngeal carcinoma
